News
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its ...
The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results